Market Spotlight: Myelodysplastic Syndrome (MDS)
Market Spotlight: Myelodysplastic Syndrome (MDS)
$1,318.00
This Market Spotlight report covers the myelodysplastic syndrome market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the myelodysplastic syndrome market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, probability of success, upcoming events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were 367,200 incident cases of myelodysplastic syndrome (MDS) worldwide, and forecasts that number to increase to 401,700 incident cases by 2026.
- Approved drugs in the MDS space target DNA methyltransferase, BCR-ABL fusion protein, KIT/c-KIT, platelet-derived growth factor receptor, erythropoietin receptor, angiogenesis, E3 ubiquitin ligase, and the immune system. These therapies are administered via the intravenous, oral, and subcutaneous routes.
- The greatest proportion of industry-sponsored drugs in active clinical development for MDS are in Phase II. Therapies in development for MDS focus on a wide variety of targets. The majority of pipeline drugs in the MDS space are administered via the intravenous or oral routes, with the remainder being subcutaneous or intradermal formulations.
- High-impact upcoming events for drugs in the MDS space comprise topline Phase II and Phase III trial results. The overall likelihood of approval of a Phase I hematologic asset is 10.7%, and the average probability a drug advances from Phase III is 57.6%. Drugs, on average, take 8.7 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
- There have been 18 licensing and asset acquisition deals involving MDS drugs during 2014–19. The $1.8bn exclusive global collaboration and license agreement made in December 2018 between Argenx and Cilag to evaluate cusatuzumab (ARGX-110), an anti-CD70 SIMPLE Antibody, in acute myeloid leukemia (AML), high-risk MDS, and other hematological malignancies was the largest deal during the period.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for MDS have been in the early and mid-phases of development, with 89% of trials in Phase I–II, and only 11% in Phase III–IV.
- The US has a substantial lead in the number of MDS clinical trials globally. France leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the MDS space is dominated by completed trials. Celgene has the highest number of completed clinical trials for MDS, with 91 trials.
- Celgene leads the industry sponsors with by far the highest number of clinical trials for MDS.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 MDS subtypes
10 TREATMENT
10 Supportive therapy
10 Growth factors
10 Chemotherapy
11 Immune treatments
11 Stem cell transplant
12 EPIDEMIOLOGY
14 MARKETED DRUGS
16 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 Luspatercept for MDS (December 2, 2018)
27 Luspatercept for MDS (June 28, 2018)
29 Imetelstat for MDS (July 31, 2017)
32 KEY UPCOMING EVENTS
33 PROBABILITY OF SUCCESS
34 LICENSING AND ASSET ACQUISITION DEALS
34 Impressive Clinical Results For Argenx’s Oncology Candidate Seal The Deal for Janssen
34 Onconova Grants Latin American Rigosertib Rights To Pint Pharma
36 PARENT PATENTS
38 REVENUE OPPORTUNITY
39 CLINICAL TRIAL LANDSCAPE
40 Sponsors by status
41 Sponsors by phase
42 Recent events
43 BIBLIOGRAPHY
43 Prescription information
45 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of MDS, 2017–26
16 Figure 2: Overview of pipeline drugs for MDS in the US
16 Figure 3: Pipeline drugs for MDS, by company
17 Figure 4: Pipeline drugs for MDS, by drug type
17 Figure 5: Pipeline drugs for MDS, by classification
27 Figure 6: Luspatercept for MDS (December 2, 2018): Phase III – MEDALIST
29 Figure 7: Luspatercept for MDS (June 28, 2018): Phase III – MEDALIST
31 Figure 8: Imetelstat for MDS (July 31, 2017): Phase II/III – Imerge (Transfusion-Dependent Subjects)
32 Figure 9: Key upcoming events in MDS
33 Figure 10: Probability of success in the MDS pipeline
34 Figure 11: Licensing and asset acquisition deals in MDS, 2014–19
36 Figure 12: Parent patents in MDS, 2020–28
37 Figure 13: Parent patents in MDS, 2029–38
39 Figure 14: Clinical trials in MDS
39 Figure 15: Top 10 drugs for clinical trials in MDS
40 Figure 16: Top 10 companies for clinical trials in MDS
40 Figure 17: Trial locations in MDS
41 Figure 18: MDS trials status
42 Figure 19: MDS trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of MDS, 2017–26
15 Table 2: Marketed drugs for MDS
18 Table 3: Pipeline drugs for MDS in the US
26 Table 4: Luspatercept for MDS (December 2, 2018)
28 Table 5: Luspatercept for MDS (June 28, 2018)
30 Table 6: Imetelstat for MDS (July 31, 2017)
38 Table 7: Historical global sales, by drug ($m), 2013–17
38 Table 8: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the